Chris Nave

Dr. Chris Nave is a Chairman at PolyActiva Pty Ltd., a Founding Partner & Managing Director at Brandon Capital Partners Pty Ltd., a Chairman at OccuRx Pty Ltd, a Chief Executive Officer at Medical Research Commercialisation Fund Trust, a Director & Member at Australian Investment Council Ltd., a Member at AusBiotech Ltd. and a Member at BioMelbourne Network.
He is on the Board of Directors at EBR Systems, Inc., Osprey Medical, Inc., Azura Ophthalmics Ltd., BACE Therapeutics Pty Ltd., Cardiora Pty Ltd., Certa Therapeutics Pty Ltd., Global Kinetics Pty Ltd., Pathios Therapeutics Ltd., QUE Oncology, Inc. and Australian Investment Council Ltd. Dr. Nave was previously employed as a Director-Commercialization by Alfred Health, a Commercialization Director by Baker Heart & Diabetes Institute, a Manager by Melbourne Ventures Pty Ltd., and a Non-Executive Director by Otifex Therapeutics Pty Ltd. He also served on the board at Athena Medicines Pty Ltd., Fibrotech Therapeutics Pty Ltd., Hatchtech Pty Ltd. and Spinifex Pharmaceuticals Pty Ltd. He received his undergraduate degree from the University of Melbourne and a doctorate degree from the University of Melbourne.